SEC Form 4 · accession 0001572426-17-000018
Nexvet Biopharma plc · NVET
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Nigel Brown
Director
Period of report
Jul 31, 2017
Accepted (ET)
Aug 2, 2017 · 9:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618561
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jul 31, 2017 | D | 7,200 | $6.72 | D | 0 | D | |
| Ordinary SharesF1,F2 | Jul 31, 2017 | D | 8,800 | $6.72 | D | 0 | I | Elsing Pty Ltd. |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to purchase ordinary sharesF3 | $0.125 | Jul 31, 2017 | D | 3,600 | D | — | Jul 1, 2019 | Ordinary Shares | 3,600 | 0 | D |
| Options to purchase ordinary sharesF4 | $0.125 | Jul 31, 2017 | D | 7,080 | D | — | Nov 5, 2020 | Ordinary Shares | 7,080 | 0 | D |
Explanation of responses
- F1Disposed of pursuant to a transaction agreement between the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired the Issuer.
- F2The reporting person has sole voting and dispositive power with respect to these reported securities.
- F3This option, which was fully vested, was cancelled in the Acquisition in exchange for a cash payment equal to $23,742.00, representing the difference between the exercise price of $0.125 per share and the $6.72 consideration per share payable in connection with in the Acquisition multiplied by the number of shares issuable on exercise of the option.
- F4This option, which was fully vested, was cancelled in the Acquisition in exchange for a cash payment equal to $46,692.60, representing the difference between the exercise price of $0.125 per share and the $6.72 consideration per share payable in connection with in the Acquisition multiplied by the number of shares issuable on exercise of the option.